Triple Helix Institute for Agriculture, Climate, and Society

Triple Helix is a biotechnology company focused on developing a novel class of gene-targeting therapeutics using peptide nucleic acids (PNAs). The company's platform utilizes triplex-forming oligonucleotides to achieve site-specific gene editing and regulation without the need for exogenous enzymes like Cas9. By targeting specific DNA sequences, Triple Helix aims to provide curative treatments for genetic disorders such as beta-thalassemia and cystic fibrosis. The technology is based on research from Yale University and the University of Connecticut, emphasizing high specificity and reduced off-target effects compared to traditional gene-editing methods.